Quick Facts
Plain-English Summary
Vilon (Lys-Glu) is a synthetic dipeptide — just two amino acids, lysine and glutamic acid — developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in the late Soviet era. It is the simplest compound in the Khavinson bioregulator series, which spans a range of tissue-derived peptides intended to act as endogenous regulators of organ function and aging. Alongside Epithalon (the telomere-associated tetrapeptide from the same group), Vilon represents the thymic branch of Khavinson's peptide library — intended to support immune system aging rather than neuroendocrine or metabolic function.
The rationale for Vilon is rooted in thymic biology. The thymus, the organ responsible for T-cell maturation, undergoes progressive involution with age — shrinking substantially after puberty and continuing to atrophy through adulthood. This thymic aging is widely considered a key driver of immunosenescence: the declining immune competence that characterises elderly populations. Vilon was proposed by the Khavinson group as a minimal functional signal derived from thymic tissue, capable of prompting T-cell precursor differentiation and partially restoring immune output in aged individuals.
The evidentiary base for Vilon is the thinnest of any compound in this catalogue. Nearly all published data originates from the Khavinson group and appeared in Russian-language journals — a subset of which has since been translated or cited in English-language gerontology literature. The primary human evidence consists of longitudinal cohort observations in elderly Russian populations receiving bioregulator complexes over 6–12 year follow-up periods. These studies reported meaningful reductions in all-cause mortality among treated cohorts; however, they carry substantial methodological limitations: they were non-randomised, open-label, confounded by polypharmacy, and conducted without placebo controls. No independent group has replicated these findings.
Vilon has the lowest public profile and the most limited independent evidence base of any compound in this catalogue. Researchers should treat all claims about this compound as preliminary and derived from a single non-independent source. External replication is completely absent as of 2026.
As a dipeptide of only 275 Da, Vilon is structurally distinguished from larger research peptides. Its small molecular weight raises questions about oral bioavailability — dipeptides can survive gastric proteolysis better than larger peptides — but also about specificity: whether such a short sequence can exert meaningful receptor-level signalling or whether observed effects in animal models reflect non-specific immune stimulation. No pharmacokinetic studies in humans have been published.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Aged mouse — immune function | Administration of Vilon in aged mice improved thymic index and T-lymphocyte counts vs. age-matched controls. Effect size modest; not replicated by independent groups. Khavinson et al. (various) ↗ | Preclinical |
| Bone marrow progenitor cultures | In vitro: Vilon promoted differentiation of haematopoietic progenitors toward T-cell lineage. IL-2 secretion increased in stimulated splenocyte cultures. Single-lab finding only. | In Vitro |
| Aged rat — survival and tumour incidence | Khavinson group reported extended median survival and reduced spontaneous tumour incidence in Sprague-Dawley rats receiving periodic Vilon administration. Significant methodological detail absent from published accounts. | Preclinical |
| Mouse — antigenic challenge | Aged mice receiving Vilon showed improved antibody titres following vaccination compared to untreated age-matched controls. Consistent with proposed thymic restoration mechanism but confounded by non-specific immune stimulation. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Longitudinal cohort — elderly St. Petersburg population | ~266 elderly patients (60–74 yrs) followed over 6–12 years; received annual bioregulator peptide complexes including Vilon | — | Confounded |
| All controlled trials | — | — | No Data |
Vilon has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
No formal toxicology studies in the Western regulatory sense have been published for Vilon. As a dipeptide composed of two naturally occurring amino acids (lysine and glutamic acid), acute toxicity is not anticipated at research doses, but this has not been systematically characterised. The absence of adverse event reports likely reflects the compound's extremely limited use rather than confirmed safety.
Immune stimulation in the context of autoimmune conditions or active inflammatory disease could theoretically be problematic. Promoting T-cell activity without understood selectivity could exacerbate conditions dependent on T-lymphocyte dysregulation. No human data exists to quantify this risk and it remains theoretical.
- Injection site redness (reported anecdotally)
- No significant adverse events in Khavinson group longitudinal data
- No pharmacovigilance database exists for Vilon
- Mention volume too low to draw signal from community reports
- Active autoimmune disease
- Active or suspected malignancy
- Immunosuppressive therapy
- Pregnancy or breastfeeding
- Children and adolescents
Vilon is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Vilon for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
I've spent time reading through the Russian bioregulator literature and Vilon is genuinely the hardest to evaluate — not because the concept is implausible, but because the data infrastructure is almost entirely missing. The longitudinal cohort work from St. Petersburg is suggestive, but the design limitations are severe enough that you can't cleanly attribute the mortality difference to Vilon specifically vs. the other peptides administered simultaneously, vs. the selection effect of elderly patients who actively sought this treatment. It's one of those situations where the signal might be real and you genuinely can't tell.
This is the correct framing. "Can't tell" is unfortunately where the evidence leaves you. The problem isn't that Khavinson's group did sloppy work — it's that the research program was never designed with the kind of controls that would let you isolate effect from noise. They were building a clinical protocol, not running a trial. That's a fundamentally different epistemological posture.
What makes Vilon structurally interesting from a pharmacology standpoint is how short it is. Two amino acids. A dipeptide of 275 Da can survive oral proteolysis far better than, say, BPC-157 at 1,400 Da. So the bioavailability question that haunts larger peptides is less severe here — Lys-Glu analogues are absorbed intact via PEPT1 transporters in the gut. The open question is whether that bioavailable form then has any meaningful receptor-level action in thymic tissue, or whether you're just absorbing a dipeptide that your body uses as building material for something else entirely.
Most people in the longevity community who use Russian bioregulators are combining them — Epithalon for the pineal/telomere angle, Vilon for thymic support, sometimes Cortagen or Cartalax for connective tissue. The idea is system-level bioregulation rather than targeting a single pathway. That's intellectually coherent if the Khavinson model is correct. The problem is that combination use makes it completely impossible to attribute any observed effect to any single peptide, which is why we don't have clean data on any of them individually. It's a research design problem baked into how the whole clinical protocol was built.
Exactly. The Khavinson protocol treats polypharmacy as a feature — the synergistic multi-organ bioregulation thesis. From a bench science standpoint it makes isolating any single compound nearly impossible. If someone ever funded a clean single-agent RCT on Vilon, even a small Phase I/II, it would be genuinely illuminating. Until then this remains an interesting hypothesis attached to longitudinally observed data that can't support causal claims.
Worth noting that thymic rejuvenation is a legitimate and active research area — the TRIIM trial (Fahy et al., 2019) showed modest thymic regeneration with GH/DHEA/metformin. Vilon's hypothesis is adjacent to this: can a short endogenous-derived peptide cue thymic stromal cells to support T-cell output in aged individuals? That's a real question. What Vilon lacks isn't conceptual grounding — it's the controlled data. If even a small-n mechanistic study showed Vilon increased naive T-cell output in elderly humans, it would change the picture substantially. Right now we just don't have that.